Soluble B-cell maturation antigen in multiple myeloma.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
revised:
19
12
2023
received:
01
11
2023
accepted:
08
01
2024
pubmed:
25
1
2024
medline:
25
1
2024
entrez:
25
1
2024
Statut:
ppublish
Résumé
B-cell maturation antigen (BCMA) has emerged as a promising immunotherapeutic target in multiple myeloma (MM) management, with the successive approval of antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptor T-cell therapies directed to this membrane receptor. Soluble BCMA (sBCMA), a truncated version produced through gamma-secretase cleavage, can be quantified in serum/plasma samples from patients with MM via electrochemiluminescence, fluorescence, or enzyme-linked immunosorbent assays, as well as through mass spectrometry-based proteomics. Besides its short serum half-life and independence from kidney function, sBCMA represents a reliable and convenient tool for MM monitoring in patients with nonsecretory or oligosecretory disease. Numerous studies have suggested a potential utility of this bioanalyte in the risk stratification of premalignant plasma cell disorders, diagnosis and prognostication of MM, and response evaluation following anti-myeloma therapies. In short, sBCMA might be the "Swiss army knife" of MM laboratory testing, but is it ready for prime time?
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
727-738Subventions
Organisme : American Society of Hematology
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Bera TK. Anti-BCMA immunotoxins: design, production, and preclinical evaluation. Biomolecules. 2020;10(10):1387. doi:10.3390/biom10101387
Yu B, Jiang T, Liu D. BCMA-targeted immunotherapy for multiple myeloma. J Hematol OncolJ Hematol Oncol. 2020;13(1):125. doi:10.1186/s13045-020-00962-7
Anderson LD, Dhakal B, Jain T, et al. Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther. 2024;30(1):17-37. doi:10.1016/j.jtct.2023.10.022
Sadek NL, Costa BA, Nath K, Mailankody S. CAR T-cell therapy for multiple myeloma: a clinical practice-oriented review. Clin Pharmacol Ther. 2023;114(6):1184-1195. doi:10.1002/cpt.3057
Dimopoulos MA, Hungria VTM, Radinoff A, et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 2023;10(10):e801-e812. doi:10.1016/S2352-3026(23)00243-0
Rodriguez-Otero P, Ailawadhi S, Arnulf B, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388(11):1002-1014. doi:10.1056/NEJMoa2213614
San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. N Engl J Med. 2023;389(4):335-347. doi:10.1056/NEJMoa2303379
Zhao J, Ren Q, Liu X, Guo X, Song Y. Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for multiple myeloma therapy: latest updates from ASCO 2023 annual meeting. J Hematol OncolJ Hematol Oncol. 2023;16(1):92. doi:10.1186/s13045-023-01489-3
Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches. Leukemia. 2020;34(4):985-1005. doi:10.1038/s41375-020-0734-z
Alomari M, Kunacheewa C, Manasanch EE. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leuk Lymphoma. 2023;64(2):261-272. doi:10.1080/10428194.2022.2133540
Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396-410. doi:10.1016/j.ccell.2017.02.002
Tai YT, Acharya C, An G, et al. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016;127(25):3225-3236. doi:10.1182/blood-2016-01-691162
Bu DX, Singh R, Choi EE, et al. Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. Oncotarget. 2018;9(40):25764-25780. doi:10.18632/oncotarget.25359
Quazi S. An overview of CAR T cell mediated B cell maturation antigen therapy. Clin Lymphoma Myeloma Leuk. 2022;22(6):e392-e404. doi:10.1016/j.clml.2021.12.003
Tai YT, Anderson KC. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma. Expert Opin Biol Ther. 2019;19(11):1143-1156. doi:10.1080/14712598.2019.1641196
Palm AKE, Henry C. Remembrance of things past: long-term B cell memory after infection and vaccination. Front Immunol. 2019;10:1787. doi:10.3389/fimmu.2019.01787
Wang Y, Li C, Xia J, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021;5(23):5290-5299. doi:10.1182/bloodadvances.2021004603
Zhang M, Gray F, Cushman I, et al. A novel BCMA immunohistochemistry assay reveals a heterogenous and dynamic BCMA expression profile in multiple myeloma. Mod Pathol. 2023;36(4):100050. doi:10.1016/j.modpat.2022.100050
Dogan A, Siegel D, Tran N, et al. B-cell maturation antigen expression across hematologic cancers: a systematic literature review. Blood Cancer J. 2020;10(6):73. doi:10.1038/s41408-020-0337-y
Pont MJ, Hill T, Cole GO, et al. γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma. Blood. 2019;134(19):1585-1597. doi:10.1182/blood.2019000050
Li D, Que Y, Ding S, et al. Anti-BCMA CAR-T cells therapy for a patient with extremely high membrane BCMA expression: a case report. J Immunother Cancer. 2022;10(9):e005403. doi:10.1136/jitc-2022-005403
Laurent SA, Hoffmann FS, Kuhn PH, et al. γ-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun. 2015;6(1):7333. doi:10.1038/ncomms8333
Sanchez E, Gillespie A, Tang G, et al. Soluble B-cell maturation antigen mediates tumor-induced immune deficiency in multiple myeloma. Clin Cancer Res. 2016;22(13):3383-3397. doi:10.1158/1078-0432.CCR-15-2224
Chen H, Yu T, Lin L, et al. γ-Secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation. Blood Cancer J. 2022;12(8):118. doi:10.1038/s41408-022-00716-3
Ghermezi M, Li M, Vardanyan S, et al. Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients. Haematologica. 2017;102(4):785-795. doi:10.3324/haematol.2016.150896
Chen H, Li M, Xu N, et al. Serum B-cell maturation antigen (BCMA) reduces binding of anti-BCMA antibody to multiple myeloma cells. Leuk Res. 2019;81:62-66. doi:10.1016/j.leukres.2019.04.008
Schmidts A, Ormhøj M, Choi BD, et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019;3(21):3248-3260. doi:10.1182/bloodadvances.2019000703
Lee H, Durante M, Ahn S, et al. The impact of soluble BCMA and BCMA gain on anti-BCMA immunotherapies in multiple myeloma. Blood. 2023;142(Supplement 1):4688. doi:10.1182/blood-2023-188080
Sanchez E, Smith EJ, Yashar MA, et al. The role of B-cell maturation antigen in the biology and management of, and as a potential therapeutic target in. Multiple Myeloma Target Oncol. 2018;13(1):39-47. doi:10.1007/s11523-017-0538-x
Stauffer A, Ray C, Hall M. A flexible multiplatform bioanalytical strategy for measurement of Total circulating shed target receptors: application to soluble B cell maturation antigen levels in the presence of a bispecific antibody drug. Assay Drug Dev Technol. 2021;19(1):17-26. doi:10.1089/adt.2020.1024
Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727-738. doi:10.1111/j.1365-2141.2012.09241.x
Jew S, Bujarski S, Soof C, et al. Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patients. Br J Haematol. 2021;192(6):1064-1067. doi:10.1111/bjh.16673
Migkou M, Avivi I, Gavriatopoulou M, et al. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Ann Hematol. 2020;99(6):1251-1255. doi:10.1007/s00277-020-03984-w
Bujarski S, Udd K, Soof C, et al. Baseline and changes in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among patients with relapsed/refractory multiple myeloma starting new therapy. Target Oncol. 2021;16(4):503-515. doi:10.1007/s11523-021-00821-6
Chawla SS, Kumar SK, Dispenzieri A, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015;95(1):57-64. doi:10.1111/ejh.12478
Kumar S, Paiva B, Anderson KC, et al. International myeloma working group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi:10.1016/S1470-2045(16)30206-6
Van Rhee F, Bolejack V, Hollmig K, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood. 2007;110(3):827-832. doi:10.1182/blood-2007-01-067728
Bujarski S, Udd K, Soof C, et al. Baseline and increases in serum B-cell maturation antigen levels rapidly indicate changes in clinical status among relapsed/refractory multiple myeloma patients undergoing new treatments. Blood. 2019;134(Supplement_1):1786. doi:10.1182/blood-2019-132012
Long TE, Indridason OS, Palsson R, et al. Defining new reference intervals for serum free light chains in individuals with chronic kidney disease: results of the iStopMM study. Blood Cancer J. 2022;12(9):133. doi:10.1038/s41408-022-00732-3
Visram A, Soof C, Rajkumar SV, et al. Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients. Blood Cancer J. 2021;11(6):120. doi:10.1038/s41408-021-00505-4
Wiedemann Á, Szita VR, Horváth R, et al. Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma. Pathol Oncol Res. 2023;29:1611171. doi:10.3389/pore.2023.1611171
Jew S, Bujarski S, Regidor B, et al. Clinical outcomes and serum B-cell maturation antigen levels in a real-world unselected population of newly diagnosed multiple myeloma patients. Target Oncol. 2023;18(5):735-747. doi:10.1007/s11523-023-00990-6
Tan W, Kunacheewa C, Becnel M, et al. OA-36 SBCMA predicts progression and is a biomarker of response in myeloma precursor disease followed on prospective studies. Clin Lymphoma Myeloma Leuk. 2023;23:S22. doi:10.1016/S2152-2650(23)01603-8
Terpos E, Ntanasis-Stathopoulos I, Malandrakis P, et al. P-167 serum BCMA levels evaluated by Elecsys sBCMA assay at diagnosis have prognostic value in patients with multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:S127-S128. doi:10.1016/S2152-2650(23)01785-8
Elmeliegy M, Kei Lon H, Wang D, et al. Soluble B-cell maturation antigen As a disease biomarker in relapsed or refractory multiple myeloma (RRMM): evaluation from Elranatamab (ELRA) Magnetismm studies. Blood. 2023;142(Supplement 1):3345. doi:10.1182/blood-2023-190341
Munshi NC, Anderson LD, Shah N, et al. Idecabtagene Vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-716. doi:10.1056/NEJMoa2024850
Shen Y, Liu J, Wang B, et al. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy. Curr Res Transl Med. 2023;71(2):103378. doi:10.1016/j.retram.2023.103378
Lowther DE, Houseman EA, Han G, et al. No evidence of BCMA expression loss or systemic immune impairment after treatment with the BCMA-targeted antibody-drug conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 trials of patients with relapsed/refractory multiple myeloma (RRMM). Blood. 2022;140(Supplement 1):611-613. doi:10.1182/blood-2022-157767
Lin Y, Raje NS, Berdeja JG, et al. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023;29(9):2286-2294. doi:10.1038/s41591-023-02496-0
Rodríguez-Otero P, Shah N, Munshi N, et al. P19: baseline correlates of complete response to IDECABTAGENE VICLEUCEL (ide-CEL, BB2121), a BCMA-directed car t cell therapy in patients with relapsed and refractory multiple myeloma: SUBANALYSIS of the KARMMA trial. HemaSphere. 2022;6:21-22. doi:10.1097/01.HS9.0000829648.85784.e2
Piasecki J, Desai K, Courtney C, et al. Baseline and early post-infusion biomarkers associated with optimal response to idecabtagene vicleucel (ide-cel) in the KarMMa-3 study of triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM). J Clin Oncol. 2023;41(16_suppl):8031. doi:10.1200/JCO.2023.41.16_suppl.8031
Zhao WH, Wang BY, Chen LJ, et al. Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2). J Hematol OncolJ Hematol Oncol. 2022;15(1):86. doi:10.1186/s13045-022-01301-8
Cohen AD, Mateos MV, Cohen YC, et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood. 2023;141(3):219-230. doi:10.1182/blood.2022015526
Piasecki J, Devries T, Radhakrishnan A, et al. Association of Baseline and Postinfusion Biomarkers with safety and efficacy endpoints in patients treated with Orvacabtagene Autoleucel (orva-cel; JCARH125) in the phase 1/2 Evolve study (NCT03430011). Blood. 2020;136(Supplement 1):2-3. doi:10.1182/blood-2020-137786
Cowan AJ, Pont MJ, Sather BD, et al. γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial. Lancet Oncol. 2023;24(7):811-822. doi:10.1016/S1470-2045(23)00246-2
Girgis S, Wang Lin SX, Pillarisetti K, et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. Blood Adv. 2023;7(4):644-648. doi:10.1182/bloodadvances.2022007625
Bahlis NJ, Costello CL, Raje NS, et al. Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial. Nat Med. 2023;29(10):2570-2576. doi:10.1038/s41591-023-02589-w
Boyapati A, Richter J, Suvannasankha A, et al. P-005 association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2023;23:S35. doi:10.1016/S2152-2650(23)01623-3
Bujarski S, Sutanto C, Spektor TM, et al. Use of serum B-cell maturation antigen levels to predict outcomes for myeloma patients treated with ruxolitinib, lenalidomide and methylprednisolone. Hematol Oncol. 2022;40(2):243-248. doi:10.1002/hon.2961
Dekhtiarenko I, Attig J, Helms HJ, et al. P-006 SBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD. Clin Lymphoma Myeloma Leuk. 2023;23:S35-S36. doi:10.1016/S2152-2650(23)01624-5
Kumar S, Rajkumar SV. Surrogate endpoints in randomised controlled trials: a reality check. The Lancet. 2019;394(10195):281-283. doi:10.1016/S0140-6736(19)31711-8
Da Vià MC, Dietrich O, Truger M, et al. Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med. 2021;27(4):616-619. doi:10.1038/s41591-021-01245-5
Samur MK, Fulciniti M, Aktas Samur A, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12(1):868. doi:10.1038/s41467-021-21177-5
Lee H, Ahn S, Maity R, et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat Med. 2023;29(9):2295-2306. doi:10.1038/s41591-023-02491-5
Samur MK, Aktas Samur A, Corre J, et al. Monoallelic deletion of BCMA is a frequent feature in multiple myeloma. Blood Adv. 2023;7(21):6599-6603. doi:10.1182/bloodadvances.2023010025
Cattaneo I, Valgardsdottir R, Cavagna R, et al. Genetic defects of gamma-secretase genes in a multiple myeloma patient with high and dysregulated BCMA surface density: a case report. Br J Haematol. 2023;1-5. doi:10.1111/bjh.19168
Zhou X, Rasche L, Kortüm KM, Mersi J, Einsele H. BCMA loss in the epoch of novel immunotherapy for multiple myeloma: from biology to clinical practice. Haematologica. 2022;108(4):958-968. doi:10.3324/haematol.2020.266841